1. Anonymous. June 21 2005. U.S. Department of Agriculture Food and Drug
Administration (FDA). Guidance for industry no. 3: general principles
for evaluation the safety of compounds used in food producing animals.
[Online.]
http://www.fda.gov/cvm
.
Accessed September
2005.
2. Anonymous. 2004
. U.S. Department of Agriculture Food Safety
Inspection Service. Section 3 p. 13-18. [Online.] 2003 FSIS
national residue program data.
www.fsis.usda.gov/PDF/2003_Red_Book_Intro.pdf
.
Accessed February
2006.
3. Anonymous. June 2005. U.S. Environmental Protection Agency National Center for
Environmental Assessment. Approaches for the application of
physiologically based pharmacokinetic (PBPK) models and supporting data
in risk assessment. EPA/600/R-05/043A external review draft. [Online.]
http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=135427
.
Accessed September
2005.
4. Bailer, A. J. 1997. An introduction to the use of physiologically based pharmacokinetic models in risk assessment.Stat. Methods Med. Res.6:341-358.
5. Bjorkman, S. 2004. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modeling: theophylline and midazolam as model drugs.Br. J. Clin. Pharmacol.59:691-704.